RecruitingPhase 2NCT06575374
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
Open Label Single Arm Pilot Trial of Letermovir for Cytomegalovirus Prophylaxis After Axicabtagene Ciloleucel Therapy
Sponsor
M.D. Anderson Cancer Center
Enrollment
36 participants
Start Date
Dec 12, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Letermovir for people with cell therapy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLetermovir
Given by mouth or intravenously
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06575374
Related Trials
Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy
NCT075051991 location
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT068399761 location
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
NCT066432211 location
MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction
NCT071833841 location